(ARKG) ARK Genomic Revolution - Overview
ETF Category: Health | Exchange BATS (USA) | Currency USD | Market Cap: 1.019m | Total Return 12.5% in 12m
Etf: Healthcare, Technology, Research, Genetics
Total Rating 31
Risk 64
Buy Signal -1.36
| Risk 5d forecast | |
|---|---|
| Volatility | 43.3% |
| Relative Tail Risk | -3.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.39 |
| Alpha | -8.29 |
| Character TTM | |
|---|---|
| Beta | 1.783 |
| Beta Downside | 1.586 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.96% |
| CAGR/Max DD | -0.12 |
Description: ARKG ARK Genomic Revolution March 04, 2026
ARKG is an actively-managed ETF focusing on the genomics revolution. It invests at least 80% of its assets in domestic and foreign equity securities.
The fund targets companies across healthcare, information technology, materials, energy, and consumer discretionary sectors. Genomics involves understanding and applying genetic information, a field with growing applications in medicine and agriculture. The business model for many genomic companies centers on research, development, and commercialization of genetic technologies and therapies.
ARKG is classified as non-diversified.
For further analysis, ValueRay can provide detailed insights into ARKGs holdings and performance.
Headlines to watch out for
- Genomic sequencing advancements boost company valuations
- Regulatory approval speed impacts biotech revenue
- Healthcare policy shifts affect genomics adoption
- Research and development costs pressure profit margins
- Global economic conditions influence healthcare spending
What is the price of ARKG shares?
As of March 29, 2026, the stock is trading at USD 25.01 with a total of 4,214,224 shares traded.
Over the past week, the price has changed by -3.99%, over one month by -16.58%, over three months by -14.41% and over the past year by +12.46%.
Over the past week, the price has changed by -3.99%, over one month by -16.58%, over three months by -14.41% and over the past year by +12.46%.
Is ARKG a buy, sell or hold?
ARK Genomic Revolution has no consensus analysts rating.
What are the forecasts/targets for the ARKG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |